ArticleCurrent opinion in physiology2026
Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs.
Article in Current opinion in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic disease is a global health epidemic with detrimental effects on reproduction. The rising use of sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have introduced new treatment options, however there is little data examining their impact on reproductive safety and efficacy during pregnancy. This review summarizes how these medications may impact hormonal regulation, limit pregnancy complications, and prevent the progression of gestational diabetes into type II diabetes post-partum. Due to safety concerns, clinical data on the use of these medications during pregnancy is limited to retrospective studies of inadvertent exposure, and the limited data on possible teratogenic effects warrants further analysis, especially considering the promising results observed in pre-clinical studies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.